Hisamitsu America is expanding the offerings from its Salonpas line of pain-relief products. The new Salonpas Arthritis Pain Relief Gel contains prescription-strength diclofenac, which was approved for over-the-counter use in 2020 by the Food and Drug Administration.
The non-greasy gel is formulated to reduce inflammation and deliver relief at the site of pain.
"Salonpas® has a long history of driving growth through our scientific approach to pain relief which includes providing the first FDA-approved OTC topical pain reliever to the public in 2008," said John Incledon, President and CEO of Hisamitsu America. "Our science-based approach is critical to our support of the Salonpas Arthritis Pain Relief Gel, as diclofenac is a globally important NSAID drug which is clinically proven to reduce arthritis pain in major joints (foot, ankle, knee, elbow, wrist, hand), and safe to use for up to 21 days."
With its focus on topical pain relief, Hisamitsu said that the Salonpas brand is the top-selling external pain relief brand in the country, according to IRI data for the 52 weeks ended Jan. 24. Hisamitsu America parent company Hisamitsu Pharmaceuticals is a global leader in transfermal drug deliver and manages Japan’s top-selling diclofenac brand.
Salonpas Arthritis Pain Relief Gel currently is available at retailers nationwide. The company is supporting the launch with a television ad campaign.